Citigroup
TCRT icon

Citigroup’s Alaunos Therapeutics TCRT Stock Holding History

Citigroup’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Sell
1
-88
-99% -$263 ﹤0.01% 5816
2025
Q4 		$287 Buy
+89
New +$288 ﹤0.01% 5623
2025
Q1 		– Sell
-1,597
Closed -$3.03K – 5956
2024
Q4 		$3.03K Buy
+1,597
New +$3.55K ﹤0.01% 5521
2023
Q4 		– Sell
-20
Closed -$394 – 5862
2023
Q3 		$394 Sell
20
-7
-26% -$302 ﹤0.01% 5240
2023
Q2 		$2.08K Buy
27
+9
+50% +$728 ﹤0.01% 5285
2023
Q1 		$1.72K Sell
18
-1,415
-99% -$135K ﹤0.01% 5107
2022
Q4 		$140K Buy
1,433
+72
+5% +$10.4K ﹤0.01% 3888
2022
Q3 		$351K Buy
1,361
+1,290
+1,817% +$375K ﹤0.01% 3482
2022
Q2 		$13K Sell
71
-79
-53% -$7.55K ﹤0.01% 5246
2022
Q1 		$15K Sell
150
-4,287
-97% -$550K ﹤0.01% 5334
2021
Q4 		$726K Buy
4,437
+894
+25% +$196K ﹤0.01% 3548
2021
Q3 		$967K Sell
3,543
-2,850
-45% -$872K ﹤0.01% 3110
2021
Q2 		$2.53M Buy
6,393
+772
+14% +$360K ﹤0.01% 2479
2021
Q1 		$3.04M Buy
5,621
+4,149
+282% +$2.58M ﹤0.01% 2194
2020
Q4 		$555K Buy
1,472
+472
+47% +$188K ﹤0.01% 4112
2020
Q3 		$377K Sell
1,000
-712
-42% -$315K ﹤0.01% 4097
2020
Q2 		$842K Buy
1,712
+5
+0.3% +$2.23K ﹤0.01% 3738
2020
Q1 		$627K Sell
1,707
-183
-10% -$94.7K ﹤0.01% 3657
2019
Q4 		$1.34M Sell
1,890
-647
-26% -$445K ﹤0.01% 3436
2019
Q3 		$1.63M Sell
2,537
-470
-16% -$373K ﹤0.01% 3096
2019
Q2 		$2.63M Buy
3,007
+2,247
+296% +$1.55M ﹤0.01% 2557
2019
Q1 		$439K Sell
760
-2,456
-76% -$1.03M ﹤0.01% 4326
2018
Q4 		$902K Buy
3,216
+1,325
+70% +$524K ﹤0.01% 3507
2018
Q3 		$908K Buy
1,891
+621
+49% +$266K ﹤0.01% 3600
2018
Q2 		$575K Sell
1,270
-865
-41% -$548K ﹤0.01% 3940
2018
Q1 		$1.26M Buy
2,135
+84
+4% +$52.4K ﹤0.01% 3049
2017
Q4 		$1.27M Buy
2,051
+1,809
+748% +$1.3M ﹤0.01% 3105
2017
Q3 		$223K Sell
242
-46
-16% -$40.9K ﹤0.01% 4903
2017
Q2 		$268K Buy
288
+86
+43% +$84.3K ﹤0.01% 4544
2017
Q1 		$192K Sell
202
-1,445
-88% -$1.35M ﹤0.01% 4691
2016
Q4 		$1.32M Buy
1,647
+1,623
+6,763% +$1.46M ﹤0.01% 3413
2016
Q3 		$21K Sell
24
-5
-17% -$4.02K ﹤0.01% 6187
2016
Q2 		$24K Sell
29
-697
-96% -$759K ﹤0.01% 6048
2016
Q1 		$809K Buy
726
+385
+113% +$394K ﹤0.01% 3586
2015
Q4 		$425K Sell
341
-154
-31% -$255K ﹤0.01% 4024
2015
Q3 		$669K Buy
495
+188
+61% +$310K ﹤0.01% 3463
2015
Q2 		$552K Buy
307
+42
+16% +$65.2K ﹤0.01% 3616
2015
Q1 		$428K Buy
265
+44
+20% +$65.2K ﹤0.01% 3900
2014
Q4 		$169K Buy
221
+83
+60% +$44.1K ﹤0.01% 4826
2014
Q3 		$55K Sell
138
-178
-56% -$85.8K ﹤0.01% 5249
2014
Q2 		$191K Buy
316
+133
+73% +$74.1K ﹤0.01% 4169
2014
Q1 		$127K Sell
183
-503
-73% -$337K ﹤0.01% 4764
2013
Q4 		$446K Buy
686
+260
+61% +$155K ﹤0.01% 3897
2013
Q3 		$251K Buy
426
+27
+7% +$12.2K ﹤0.01% 3969
2013
Q2 		$126K Buy
+399
New +$111K ﹤0.01% 4660

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's TCRT Position: Q1 2026 in Review

Citigroup reduced its Alaunos Therapeutics (TCRT) stake by 99% in Q1 2026, selling an estimated $263 and leaving 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5816.

Citigroup first reported a position in TCRT in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.04M in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Citigroup held 1 share of Alaunos Therapeutics worth $3 as of Q1 2026.
  • Citigroup sold 88 Alaunos Therapeutics shares in Q1 2026, an estimated $263.
  • Alaunos Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5816 holding.
  • Citigroup first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • Citigroup's Alaunos Therapeutics position peaked at $3.04M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.